You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Access Support Programs

PATIENT ASSISTANCE PROGRAM

TOGETHER with TESAROTM

TOGETHER with TESARO™ offers solutions to address medication access and affordability throughout each patient's experience. Our expert case management team facilitates the process of helping healthcare providers and their patients being treated with our medicines get the individualized support needed. We provide access and affordability solutions, so healthcare providers and people living with cancer can focus on what's important—patients and their well-being. 

Learn about TOGETHER with TESAROTM

EXPANDED ACCESS PROGRAMS

Niraparib Expanded Access Program in the United States

Given the commercial availability of niraparib in the US, the EAP is now closed to new enrollment for people in the US. 

Niraparib Expanded Access Program Outside the United States

TESARO offers an EAP for niraparib in Europe for individuals who meet the program's inclusion criteria. European-based healthcare professionals can obtain details about the niraparib EAP by calling +44 1283 494 340 or by emailing customer.services@clinigengroup.com.

Niraparib is currently being evaluated in a comprehensive, international clinical development program that includes TESARO-sponsored and investigator-sponsored research in ovarian cancer and other cancers. People living with cancer or physicians seeking more information about local studies in the US, please visit www.clinicaltrials.gov. For more information about local studies in Europe, please visit www.clinicaltrialsregister.eu.

TESARO has established a comprehensive development program to evaluate the safety and efficacy of niraparib in people with ovarian and breast cancer. Additional registrational studies in the settings of metastatic ovarian, breast, and lung cancers are also planned. A number of investigator-led studies of niraparib are also ongoing. For more information about ongoing clinical studies of niraparib, please visit www.clinicaltrials.gov or www.clinicaltrialsregister.eu.